A long-running controversy around compensating patients in India who had been implanted with DePuy’s faulty ASR hip system has come to a boil, with a government constituted expert panel recommending that such patients be duly compensated.
The panel has, among a string of recommendations, set a base compensation of INR2m ($28,280.50) per patient and recommended that Johnson & Johnson's orthopedics company (referred to as DePuy Synthes after the big merger in 2012, post-ASR recall) extend the ASR “reimbursement” program until 2025
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?